• Parabilis Medicines appointed Craig L. Tendler, M.D., to its board of directors on Aug. 25, 2026.
• Tendler previously led late-stage clinical development and global medical affairs for oncology at Johnson & Johnson.
• He will continue to serve as a scientific adviser while taking on board duties.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Parabilis Medicines Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608250700PRIMZONEFULLFEED9815352) on August 25, 2026, and is solely responsible for the information contained therein.